For example, pVLTrap, a 6.7 kb retroviral plasmid vector containing two long terminal repeats (LTRs, known to cause stability problems) was produced successfully in DH5α at 785 mg/L using the ...

Non-viral (primarily plasmid-based) gene therapy raises fewer safety concerns, 1 and is not hampered by immunogenicity to vector-specific sequences or products, permitting re-administration.

Plasmids that are used experimentally for these purposes are called vectors. Researchers can insert DNA fragments or genes into a plasmid vector, creating a so-called recombinant plasmid.

Molecular biology is an ever-changing field, and most significant developments have happened because of changes in plasmid DNA sequencing. A plasmid, a circular and small double-stranded DNA entity ...

Processes yielding >500 mg plasmid DNA/L have previously been reported by Merck, Boehringer Ingelheim, and Nature Technology (NTC). Common features among these high-yield processes include the use ...

CDMOs account for over 60% of outsourced viral vector manufacturing services. The demand for GMP-grade plasmid DNA has surged by over 200% since 2021. FDA approvals for gene therapies doubled between ...